TZP-102, Ghrelin Agonist Phase 2 Data: The Improvement in Symptoms of Gastroparesis (Nausea, Early Satiety, Bloating and Abdominal Pain) Significantly Correlated With Patient Rating of Overall Treatment Effect

* Percentage of patients with a score ≥ 1 **Where 0=none,1=very mild, 2=mild, 3=moderate, 4=severe, and 5=very severe for individual symptoms. TZP-102, Ghrelin Agonist, Phase 2 Data: The Improvement in Symptoms of Gastroparesis (Nausea, Early Satiety, Bloating and Abdominal Pain) Significantly Correlated with Patient Rating of Overall Treatment Effect R McCallum1, J Wo2, R Venuti3, T Esfandyari4, M Jamal5, G Dimcevski6, L Tarnow7, R Malik8, PM Hellstom9, L Shaughnessy3, P Charlton3, G Kosutic3, N Ejskjaer10 1Texas Tech Univ Health Sci Ctr El Paso TX, 2Univ Louisville, Louisville KY, 3Tranzyme, Inc., Durham NC, 4Univ Kansas Med Ctr, Kansas City KS; 5Long Beach VA Med Ctr, Long Beach CA, 6Haukeland Univ Hosp, Bergen NO, 7Steno Diabetes Ctr, Gentofte DK, 8Univ Manchester, Manchester UK, 9Uppsala Univ Hosp, Uppsala SE, 10Aarhus Univ Hosp, Aarhus DK